Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

Journal: Nature Immunology

Published: 2020-01-20

DOI: 10.1038/s41590-019-0578-8

Affiliations: 10

Authors: 19

Go to article
Institutions Share
Institute of Infection and Immunity, Cardiff University, United Kingdom (UK) 0.56
Division of Hematology and Hematologic Malignancies, Utah, United States of America (USA) 0.11
Systems Immunity Research Institute, Cardiff University, United Kingdom (UK) 0.09
Institute of Cancer and Genetics, Cardiff University, United Kingdom (UK) 0.05
Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Denmark 0.05
University of Copenhagen (UCPH), Denmark 0.05
The Peter Doherty Institute for Infection and Immunity (Doherty Institute), Australia 0.05
Monash University, Australia 0.01
Infection and Immunity Program, Monash University, Australia 0.01
Department of Biochemistry and Molecular Biology, Monash University, Australia 0.01

Return

Except where otherwise noted © 2020 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER